This activity is expired and is no longer available for CME credit.


Report on the First Experience with Integrin Peptide Therapy in Patients with DME

Author(s)/Faculty: David S. Boyer, MD
Release Date: 5/11/2012Expiration Date: 5/10/2014
Credit Type: CMENumber of Credits: 0
Content Type: Provider:
This was the first human exposure to ALG-1001. The study objective was evaluating safety in human subjects. There was consistency in the lack of toxicity across all study metrics. Overall, ALG-1001 was very well tolerated. Despite the small study size, there has been a clinically significant indicator of efficacy with improvements in BCVA tracking anatomic improvements in OCT central macular thickness. The clinical improvements endured to the end of the study at least 90 days past the last intravitreal treatment in nearly all study subjects that demonstrated improvements...